Advertisement

Cardiovascular Risk of Migraine in Men and Women

  • L. Al-Hassany
  • K. A. Linstra
  • G. M. Terwindt
  • Antoinette Maassen van den BrinkEmail author
Chapter
Part of the Headache book series (HEAD)

Abstract

The association of migraine, particularly migraine with aura—characterized by focal neurological symptoms—and different forms of cardiovascular disease and cardiovascular mortality has been a topic of much debate. However, with recent advances made in this field, migraine with aura has now been acknowledged as an established risk factor for (subclinical) ischemic lesions in the brain and white matter lesions. Moreover, a broader range of ischemic vascular disorders, including myocardial ischemia, has been studied. Although migraine mainly affects young women and the majority of data available on an association with cardiovascular disease is based on females, an association between migraine and cardiovascular disease has also been observed in men. The assumption that the presence or absence of cardiovascular disease influences the additional cardiovascular risk associated with migraine therefore may have consequences for the choices of pharmacological antimigraine treatment.

References

  1. 1.
    Sacco SCA. Migraine: an emerging cardiovascular risk factor. Cardiol Clin Pract. 2010;2(1):53–65.Google Scholar
  2. 2.
    Bigal ME, Kurth T, Hu H, Santanello N, Lipton RB. Migraine and cardiovascular disease: possible mechanisms of interaction. Neurology. 2009;72(21):1864–71.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Tepper D. Migraine and cardiovascular disease. Headache. 2014;54(7):1267–8.PubMedGoogle Scholar
  4. 4.
    Hu X, Zhou Y, Zhao H, Peng C. Migraine and the risk of stroke: an updated meta-analysis of prospective cohort studies. Neurol Sci. 2017;38(1):33–40.PubMedGoogle Scholar
  5. 5.
    Linstra KM, Ibrahimi K, Terwindt GM, Wermer MJ, MaassenVanDenBrink A. Migraine and cardiovascular disease in women. Maturitas. 2017;97:28–31.PubMedGoogle Scholar
  6. 6.
    Sacco S, Bushell C. Cardio-cerebrovascular comorbidity. In: Giamberardino MA, Martelletti P, editors. Comorbidities of headache disorders. New York, NY: Springer; 2017. p. 1–21.Google Scholar
  7. 7.
    Schurks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T. Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ. 2009;339:b3914.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Sacco S, Ornello R, Ripa P, Tiseo C, Degan D, Pistoia F, et al. Migraine and risk of ischaemic heart disease: a systematic review and meta-analysis of observational studies. Eur J Neurol. 2015;22(6):1001–11.PubMedGoogle Scholar
  9. 9.
    Kurth T, Winter AC, Eliassen AH, Dushkes R, Mukamal KJ, Rimm EB, et al. Migraine and risk of cardiovascular disease in women: prospective cohort study. BMJ. 2016;353:i2610.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Wang YC, Lin CW, Ho YT, Huang YP, Pan SL. Increased risk of ischemic heart disease in young patients with migraine: a population-based, propensity score-matched, longitudinal follow-up study. Int J Cardiol. 2014;172(1):213–6.PubMedGoogle Scholar
  11. 11.
    Bigal ME, Kurth T, Santanello N, Buse D, Golden W, Robbins M, et al. Migraine and cardiovascular disease: a population-based study. Neurology. 2010;74(8):628–35.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Gudmundsson LS, Scher AI, Aspelund T, Eliasson JH, Johannsson M, Thorgeirsson G, et al. Migraine with aura and risk of cardiovascular and all cause mortality in men and women: prospective cohort study. BMJ. 2010;341:c3966.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Kurth T, Gaziano JM, Cook NR, Bubes V, Logroscino G, Diener HC, et al. Migraine and risk of cardiovascular disease in men. Arch Intern Med. 2007;167(8):795–801.PubMedGoogle Scholar
  14. 14.
    Ahmed B, Bairey Merz CN, McClure C, Johnson BD, Reis SE, Bittner V, et al. Migraines, angiographic coronary artery disease and cardiovascular outcomes in women. Am J Med. 2006;119(8):670–5.PubMedGoogle Scholar
  15. 15.
    Velentgas P, Cole JA, Mo J, Sikes CR, Walker AM. Severe vascular events in migraine patients. Headache. 2004;44(7):642–51.PubMedGoogle Scholar
  16. 16.
    Hall GC, Brown MM, Mo J, MacRae KD. Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice. Neurology. 2004;62(4):563–8.PubMedGoogle Scholar
  17. 17.
    Sternfeld B, Stang P, Sidney S. Relationship of migraine headaches to experience of chest pain and subsequent risk for myocardial infarction. Neurology. 1995;45(12):2135–42.PubMedGoogle Scholar
  18. 18.
    Schwedt TJ. The migraine association with cardiac anomalies, cardiovascular disease, and stroke. Neurol Clin. 2009;27(2):513–23.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Alqaqa A. The Association of cardiovascular disease and migraine: review. J Clini Exp Cardiol. 2016;7(8):465.Google Scholar
  20. 20.
    Kruit MC, Van Buchem MA, Hofman PAM, Bakkers JTN, Terwindt GM, Ferrari MD, Launer LJ. Migraine as a risk factor for subclinical brain lesions. JAMA. 2004;291(4):427–34.PubMedGoogle Scholar
  21. 21.
    Sacco S, Merki-Feld GS, Ægidius KL, Bitzer J, Canonico M, Kurth T, et al. Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC). J Headache Pain. 2017;18(1):108.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol. 2003;23(2):168–75.PubMedGoogle Scholar
  23. 23.
    Sacco S, Ripa P, Grassi D, Pistoia F, Ornello R, Carolei A, et al. Peripheral vascular dysfunction in migraine: a review. J Headache Pain. 2013;14:80.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Settakis G, Lengyel A, Molnár C, Bereczki D, Csiba L, Fülesdi B. Transcranial doppler study of the cerebral hemodynamic changes during breath-holding and hyperventilation tests. J Neuroimaging. 2002;12:252–8.PubMedGoogle Scholar
  25. 25.
    Ibrahimi K, De Graaf Y, Draijer R, Danser AHJ, Maassen VanDenBrink A, Van den Meiracker AH. Reproducibility and agreement of Different non-invasive methods of endothelial function assessment. Microvasc Res. 2018;117:50–6.PubMedGoogle Scholar
  26. 26.
    Butt JH, Franzmann U, Kruuse C. Endothelial function in migraine with aura - a systematic review. Headache. 2015;55(1):35–54.PubMedGoogle Scholar
  27. 27.
    Kernick D. Statins for all: should patients who have migraine with aura be on a statin? Br J Gen Pract. 2015;65(640):571–2.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Hanington E. Migraine: the platelet hypothesis after 10 years. Biomed Pharmacother. 1989;43(10):719–26.PubMedGoogle Scholar
  29. 29.
    Danese E, Montagnana M, Lippi G. Platelets and migraine. Thromb Res. 2014;134(1):17–22.PubMedGoogle Scholar
  30. 30.
    Govitrapong P, Limthavon C, Srikiatkhachorn A. 5-HT2 serotonin receptor on blood platelet of migraine patients. Headache. 1992;32(10):480–4.PubMedGoogle Scholar
  31. 31.
    Kozubski W, Walkowiak B, Cierniewski CS, Prusinski A. Platelet fibrinogen receptors in migraine patients. Headache. 1987;27(8):431–4.PubMedGoogle Scholar
  32. 32.
    Pawlowska Z, Kozubski W, Walkowiak B, Cierniewski CS. Increased platelet glycoprotein IIb reflects an abnormality of the platelet membrane in migraine. Headache. 1988;28(1):60.PubMedGoogle Scholar
  33. 33.
    Gupta VK. Patent foramen ovale closure and migraine: science and sensibility. Expert Rev Neurother. 2010;10(9):1409–22.PubMedGoogle Scholar
  34. 34.
    Silva IRFG. Migraine patients should be cautiously followed for risk factors leading to cardiovascular disease. Arq Neuropsiquiatr. 2013;71(2):119–24.PubMedGoogle Scholar
  35. 35.
    Dowson AJ, Wilmshurst P, Muir KW, et al. A prospective, multicentre, double-blind, placebo-controlled study to evaluate the efficacy of patent foramen ovale closure for the resolution of refractory migraine headache (the MIST Study): prevalence and size of shunts. Headache Care. 2005;2(4):223–7.Google Scholar
  36. 36.
    Colson NJ, Fernandez F, Lea RA, Griffiths LR. The search for migraine genes: an overview of current knowledge. Cell Mol Life Sci. 2007;64(3):331–44.PubMedGoogle Scholar
  37. 37.
    Gormley P, Anttila V, Winsvold BS, et al. Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine. Nat Genet. 2016;48(8):856–66.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Winsvold BS, Bettella F, Witoelar A, Anttila V, Gormley P, Kurth T, et al. Shared genetic risk between migraine and coronary artery disease: a genome-wide analysis of common variants. PLoS One. 2017;12(9):e0185663.PubMedPubMedCentralGoogle Scholar
  39. 39.
    Weitzel KW, Strickland JM, Smith KM, Goode JV. Gender-specific issues in the treatment of migraine. J Gend Specif Med. 2001;4(1):64–74.PubMedGoogle Scholar
  40. 40.
    Sacco S, Ricci S, Degan D, Carolei A. Migraine in women: the role of hormones and their impact on vascular diseases. J Headache Pain. 2012;13(3):177–89.PubMedPubMedCentralGoogle Scholar
  41. 41.
    Cook NR, Benseñor IM, Lotufo PA, Lee I, Skerrett PJ, Chown MJ, Ajani UA, Manson JE, Buring JE. Migraine and coronary heart disease in women and men. Headache. 2002;42:715–27.PubMedGoogle Scholar
  42. 42.
    Cook NR, Bensenor IM, Lotufo PA, Lee IM, Skerrett PJ, Chown MJ, et al. Migraine and coronary heart disease in women and men. Headache. 2002;42(8):715–27.PubMedGoogle Scholar
  43. 43.
    Chai NC, Peterlin BL, Calhoun AH. Migraine and estrogen. Curr Opin Neurol. 2014;27(3):315–24.PubMedPubMedCentralGoogle Scholar
  44. 44.
    Gupta S, Mehrotra S, Villalon CM, Perusquia M, Saxena PR, MaassenVanDenBrink A. Potential role of female sex hormones in the pathophysiology of migraine. Pharmacol Ther. 2007;113(2):321–40.PubMedGoogle Scholar
  45. 45.
    Rosano GM, Leonardo F, Sarrel PM, Beale CM, De Luca F, Collins P. Cyclical variation in paroxysmal supraventricular tachycardia in women. Lancet. 1996;347(9004):786–8.PubMedGoogle Scholar
  46. 46.
    Lloyd GW, Patel NR, McGing E, Cooper AF, Brennand-Roper D, Jackson G. Does angina vary with the menstrual cycle in women with premenopausal coronary artery disease? Heart. 2000;84(2):189–92.PubMedPubMedCentralGoogle Scholar
  47. 47.
    Choo WK. Menstruation angina: a case report. J Med Case Reports. 2009;3:6618.PubMedCentralGoogle Scholar
  48. 48.
    Tietjen GE, Khubchandani J. Vascular biomarkers in migraine. Cephalalgia. 2015;35(2):95–117.PubMedGoogle Scholar
  49. 49.
    Tietjen GE, Khubchandani J, Herial N, Palm-Meinders IH, Koppen H, Terwindt GM, et al. Migraine and vascular disease biomarkers: a population-based case-control study. Cephalalgia. 2018;38:511.PubMedGoogle Scholar
  50. 50.
    Rose KM, Wong TY, Carson AP, Couper DJ, Klein R, Sharrett AR. Migraine and retinal microvascular abnormalities: the Atherosclerosis Risk in Communities Study. Neurology. 2007;68(20):1694–700.PubMedGoogle Scholar
  51. 51.
    Stam AH, Weller CM, Janssens ACJW, Aulchenko YS, Oostra BA, Frants RR, Van den Maagdenberg AMJM, Ferrari MD, Van Duijn CM, Terwindt GM. Migraine is not associated with enhanced atherosclerosis. Cephalalgia. 2013;33(4):228–35.PubMedGoogle Scholar
  52. 52.
    Kurth T, Diener HC. Migraine and stroke: perspectives for stroke physicians. Stroke. 2012;43(12):3421–6.PubMedGoogle Scholar
  53. 53.
    Chang CL, Donaghy M, Poulter N. Migraine and stroke in young women: case-control study. The World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. BMJ. 1999;318(7175):13–8.PubMedPubMedCentralGoogle Scholar
  54. 54.
    Gilad R, Boaz M, Dabby R, Finkelstein V, Rapoport A, Lampl Y. Migraine and vascular risk factors in the elderly. Geriatr Gerontol Int. 2014;14(1):220–5.PubMedGoogle Scholar
  55. 55.
    John S, Schneider MP, Delles C, Jacobi J, Schmieder RE. Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. Am Heart J. 2005;149(3):473.PubMedGoogle Scholar
  56. 56.
    Kurth T, Diener HC, Buring JE. Migraine and cardiovascular disease in women and the role of aspirin: subgroup analyses in the Women’s Health Study. Cephalalgia. 2011;31(10):1106–15.PubMedPubMedCentralGoogle Scholar
  57. 57.
    Roberto G, Raschi E, Piccinni C, Conti V, Vignatelli L, D’Alessandro R, et al. Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: systematic review of observational studies. Cephalalgia. 2015;35(2):118–31.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • L. Al-Hassany
    • 1
  • K. A. Linstra
    • 1
    • 2
  • G. M. Terwindt
    • 2
  • Antoinette Maassen van den Brink
    • 1
    Email author
  1. 1.Divisionof Pharmacology and Vascular Medicine, Department of Internal MedicineErasmus University Medical CenterRotterdamThe Netherlands
  2. 2.Department of NeurologyLeiden University Medical CenterLeidenThe Netherlands

Personalised recommendations